Glenmark Pharmaceuticals has informed that it has enclosed a media release on 23rd March 2021, titled ‘Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 60 mg, 90 mg, and 120 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity’ which is self?explanatory.
The above information is a part of company’s filings submitted to BSE.